SEC Form 4 · accession 0001193125-26-275964
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James N Wilson
Director
Period of report
Jun 16, 2026
Accepted (ET)
Jun 18, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F4 | Jun 16, 2026 | S | 4,177 | $82.6948 | D | 1,100,366 | I | James N. Wilson and Pamela D. Wilson Trust |
| Common StockF3,F4 | Jun 16, 2026 | S | 5,823 | $83.5708 | D | 1,094,543 | I | James N. Wilson and Pamela D. Wilson Trust |
| Common Stock | holding | — | — | — | 200,000 | I | James N. Wilson 2025 Grantor Retained Annuity Trust | |
| Common Stock | holding | — | — | — | 200,000 | I | Pamela D. Wilson 2025 Grantor Retained Annuity Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
- F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.13 to $83.125 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.16 to $83.935 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Remarks
The power of attorney under which this form was signed is on file with the Commission.